Liminatus Pharma, Inc. Class A Common Stock Market Cap ($3.38 Million)
Market Cap & Net Worth: Liminatus Pharma, Inc. Class A Common Stock (LIMN)
Liminatus Pharma, Inc. Class A Common Stock market cap. Liminatus Pharma, Inc. Class A Common Stock (NASDAQ:LIMN) has a market capitalization of $3.38 Million ($3.38 Million) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29245 globally and #5986 in its home market, demonstrating a -14.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Liminatus Pharma, Inc. Class A Common Stock's stock price $2.52 by its total outstanding shares 1343207 (1.34 Million). Also see LIMN operating cash flow for how efficiently the company converts equity into cash flow.
Liminatus Pharma, Inc. Class A Common Stock Market Cap History (2025–2026)
Liminatus Pharma, Inc. Class A Common Stock market cap history from 2025 to 2026. Data shows change from $819.36K to $3.38 Million (-53.76% CAGR). Check LIMN stock price and chart for real-time trading data and today's change.
Liminatus Pharma, Inc. Class A Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Liminatus Pharma, Inc. Class A Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Liminatus Pharma, Inc. Class A Common St annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LIMN by Market Capitalization
Companies near Liminatus Pharma, Inc. Class A Common Stock in the global market cap rankings as of November 3, 2026. Also see Liminatus Pharma, Inc. Class A Common St (LIMN) total assets for a full breakdown of the balance sheet.
Key companies related to Liminatus Pharma, Inc. Class A Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Liminatus Pharma, Inc. Class A Common Stock (2025–2026)
Market capitalization of Liminatus Pharma, Inc. Class A Common Stock from 2025 to today. Between 2025 and today, Liminatus Pharma, Inc. Class A Common Stock's market cap moved from $819.36K to $ 3.38 Million, with a yearly change of -53.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.38 Million | +313.11% |
| 2025 | $819.36K | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Liminatus Pharma, Inc. Class A Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.38 Million USD |
| MoneyControl | $3.38 Million USD |
| MarketWatch | $3.38 Million USD |
| marketcap.company | $3.38 Million USD |
| Reuters | $3.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.